Lipoxygenase (LOX) signaling in epilepsy: Pathophysiology and therapeutic prospects

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Epilepsy affects 1-2% of the global population, with many experiencing drug-resistant seizures despite current treatments.
• Neuroinflammation, driven by the arachidonic acid cascade and lipoxygenase (LOX) enzymes, is increasingly recognized as a key factor in epilepsy development (epileptogenesis).
• Dysregulated LOX activity contributes to neuronal damage, glial activation, and blood-brain barrier issues, exacerbating epilepsy.

Purpose of the Study:

• To review the role of lipoxygenase (LOX) pathways in epilepsy pathophysiology.
• To explore the therapeutic potential of targeting 5-LOX and 12/15-LOX for managing seizure disorders.
• To integrate preclinical evidence and mechanistic insights for developing novel epilepsy therapies.

Main Methods:

• Literature review of preclinical studies and mechanistic insights.
• Analysis of the role of arachidonic acid metabolism in neuroinflammation and epileptogenesis.
• Evaluation of the impact of LOX enzyme activity on neuronal function and survival.

Main Results:

• Lipoxygenase (LOX) enzymes, particularly 5-LOX and 12/15-LOX, are implicated in oxidative stress, lipid peroxidation, and pro-inflammatory signaling in epilepsy.
• Inhibition of LOX pathways shows potential in preclinical models for reducing seizure frequency and severity.
• Targeting LOX may also address neuropsychiatric comorbidities associated with epilepsy.

Conclusions:

• Lipoxygenase (LOX) pathways represent a significant therapeutic target for epilepsy and its associated neurological conditions.
• Further research into 5-LOX and 12/15-LOX inhibitors could lead to more effective and safer treatments for drug-resistant epilepsy.
• Targeting neuroinflammation via LOX inhibition offers a promising avenue for future therapeutic innovation in epilepsy care.